Abeona Therapeutics Inc (NASDAQ:ABEO) Forecasted to Post FY2024 Earnings of ($2.38) Per Share

Abeona Therapeutics Inc (NASDAQ:ABEO) – Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Abeona Therapeutics in a research note issued on Wednesday, April 24th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($2.38) per share for the year, down from their prior forecast of ($1.86). Cantor Fitzgerald has a “Overweight” rating and a $36.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($2.05) per share.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13).

Separately, StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $3.26 on Friday. The business’s fifty day moving average price is $7.23 and its two-hundred day moving average price is $5.60. Abeona Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $9.01. The stock has a market capitalization of $89.16 million, a price-to-earnings ratio of -1.26 and a beta of 1.49.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, SVP Brendan M. O’malley bought 8,600 shares of the firm’s stock in a transaction dated Thursday, April 25th. The shares were bought at an average price of $3.24 per share, for a total transaction of $27,864.00. Following the completion of the acquisition, the senior vice president now owns 188,718 shares of the company’s stock, valued at $611,446.32. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Abeona Therapeutics

Large investors have recently made changes to their positions in the business. Simplex Trading LLC grew its holdings in shares of Abeona Therapeutics by 1,889.9% during the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 13,418 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter worth $199,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Abeona Therapeutics during the third quarter valued at $648,000. Worth Venture Partners LLC lifted its stake in shares of Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after acquiring an additional 121,969 shares during the period. Finally, Barclays PLC lifted its stake in shares of Abeona Therapeutics by 100.0% during the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 185,638 shares during the period. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.